5 Key Takeaways

• 1

  Aleniglipron reduced body weight by 9% to 12% at 36 weeks in adults with obesity or overweight, compared to 1% with placebo.

• 2

  The ACCESS trial involved 230 patients, aged 18 to 79 years, with a mean BMI of 39.5 kg/m² and a mean weight of 114.8 kg.

• 3

  Gastrointestinal adverse events were common, occurring in 79% to 89% of aleniglipron-treated patients, with nausea being the most frequent.

• 4

  At week 56, mean weight loss was 13.3%, 16.2%, and 15.3% for patients initially assigned to 45 mg, 90 mg, and 120 mg, respectively.

• 5

  The study had limitations, including a predominantly White population and lower female participation compared to other obesity trials.